SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi for…Original Article
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
